These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 14601046)

  • 1. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
    Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
    Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
    Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
    Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
    Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
    Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
    Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
    Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
    Stiborová M; Bieler CA; Wiessler M; Frei E
    Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
    Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
    Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
    Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
    Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.
    Kotrbová V; Mrázová B; Moserová M; Martínek V; Hodek P; Hudeček J; Frei E; Stiborová M
    Biochem Pharmacol; 2011 Sep; 82(6):669-80. PubMed ID: 21683692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
    Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
    Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
    Martinkova E; Dontenwill M; Frei E; Stiborova M
    Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
    Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
    Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
    Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study.
    Stiborova M; Manhartova Z; Hodek P; Adam V; Kizek R; Frei E
    Sensors (Basel); 2014 Dec; 14(12):22982-97. PubMed ID: 25479328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
    Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
    Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.
    Stiborova M; Moserova M; Mrazova B; Kotrbova V; Frei E
    Neuro Endocrinol Lett; 2010; 31 Suppl 2():26-35. PubMed ID: 21187821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
    Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
    Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.